Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A
Public ClinicalTrials.gov record NCT05500807. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Emicizumab for Severe VON Willebrand Disease (VWD) and VWD/Hemophilia A
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Von Willebrand Disease (VWD) is the most common inherited bleeding disorder affecting up to 0.1% of the population, is usually characterized by mucocutaneous bleeding, HMB, surgical bleeding or other hemostatic challenges. Severe bleeding events require VWF concentrates administered solely through intravenous access. Emicizumab (Hemlibra) is a monoclonal bispecific antibody developed to bind activated FIX and FX and mimic FVIII cofactor functionality. Hemlibra is administered via subcutaneous injection rather than intravenous infusion. The hypothesis of this study is that Emicizumab is safe and efficacious for prophylaxis in severe VWD and concomitant VWD/hemophilia patients.
Study identification
- NCT ID
- NCT05500807
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 40 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 0 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2022
- Primary completion
- May 31, 2027
- Completion
- Jan 31, 2028
- Last update posted
- Apr 2, 2026
2022 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders (CIBD) | Orange | California | 92868 | Recruiting |
| Stanford University: Stanford Children's Health | Redwood City | California | 94063 | Recruiting |
| University of Miami - Miller School of Medicine | Coral Gables | Florida | 33146 | Recruiting |
| St. Joseph's Children's Hospital - Center for Bleeding and Clotting Disorders | Tampa | Florida | 33607 | Recruiting |
| Bleeding and Clotting Disorders Institute (BCDI) | Peoria | Illinois | 61614 | Recruiting |
| Innovative Hematology, Inc. (IHI) | Indianapolis | Indiana | 46260 | Recruiting |
| University of Michigan Medical School | Ann Arbor | Michigan | 48109 | Recruiting |
| Central Michigan University: Children's Hospital of Michigan | Mount Pleasant | Michigan | 48859 | Recruiting |
| Children's Mercy Hospital | Kansas City | Missouri | 64108 | Recruiting |
| Penn State College of Medicine | Hershey | Pennsylvania | 17033 | Recruiting |
| Washington Center for Bleeding Disorders | Seattle | Washington | 98101 | Recruiting |
| UW Health Comprehensive Program for Bleeding Disorders | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05500807, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05500807 live on ClinicalTrials.gov.